Real-World Evidence Confirms Risk Stratification of the 31-GEP and i31-GEP in Prospectively Tested Patients With Stage I-III Cutaneous Melanoma . J of Skin 2024, 8 (2), s386. https://doi.org/10.25251/skin.8.supp.386.